Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 5c; Guides FY11
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $246.81 -0.31%
EPS Growth %: -20.5%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -20.5%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $61.86 million.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
